Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2017 Jul 1;109(7):djw307.
doi: 10.1093/jnci/djw307.

Breast Cancer Patient-Derived Xenografts: Pros, Cons, and Next Steps

Maryam Nemati Shafaee  1 , Matthew James Ellis  1
Affiliations
Comment

Breast Cancer Patient-Derived Xenografts: Pros, Cons, and Next Steps

Maryam Nemati Shafaee et al. J Natl Cancer Inst. .
No abstract available

PubMed Disclaimer

Comment on

  • Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer.
    Goetz MP, Kalari KR, Suman VJ, Moyer AM, Yu J, Visscher DW, Dockter TJ, Vedell PT, Sinnwell JP, Tang X, Thompson KJ, McLaughlin SA, Moreno-Aspitia A, Copland JA, Northfelt DW, Gray RJ, Hunt K, Conners A, Sicotte H, Eckel-Passow JE, Kocher JP, Ingle JN, Ellingson MS, McDonough M, Wieben ED, Weinshilboum R, Wang L, Boughey JC. Goetz MP, et al. J Natl Cancer Inst. 2017 Jul 1;109(7):djw306. doi: 10.1093/jnci/djw306. J Natl Cancer Inst. 2017. PMID: 28376176 Free PMC article.

References

    1. Nik-Zainal S, Davies H, Staaf J, et al.Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2016;5347605:47–54. - PMC - PubMed
    1. DeRose YS, Wang G, Lin YC, et al.Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med. 2011;1711:1514–1520. - PMC - PubMed
    1. Ding L, Ellis MJ, Li S, Larson DE, et al.Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature. 2010;4647291:999–1005. - PMC - PubMed
    1. Li S, Shen D, Shao J, Crowder R, et al.Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep. 2013;46:1116–1130. - PMC - PubMed
    1. Lu J, McEachern D, Li S, Ellis MJ, Wang S. Reactivation of p53 by MDM2 Inhibitor MI-77301 for the treatment of endocrine-resistant breast cancer. Mol Cancer Ther. 2016;1512:2887–2893. - PMC - PubMed